Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.44 |
| ▸ | ACVR1B | P36896 | 9/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21177222 | 0.91 | TGFBR1 (0.46) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| Hydrochloric Acid SCHEMBL21177245 | 0.90 | TGFBR1 (0.45) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL21177451 | 0.89 | TGFBR1 (0.43) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| Hydrochloric Acid SCHEMBL21177466 | 0.89 | TGFBR1 (0.42) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL22052992 | 0.85 | TGFBR1 (0.44) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL21177216 | 0.85 | MAPK8 (0.38) | TGFBR1MAPK8CAMKK2PIK3CGGSK3B | |
| SCHEMBL21177224 | 0.84 | MAPK8 (0.35) | MAPK8CAMKK2PIK3CGGSK3BHDAC1 | |
| SCHEMBL21987108 | 0.76 | JAK2 (0.38) | MAPK8CAMKK2PIK3CGGSK3B | |
| SCHEMBL21177212 | 0.76 | CAMKK2 (0.36) | TGFBR1ACVR1BMAPK8CAMKK2PIK3CG | |
| SCHEMBL21177267 | 0.76 | PIK3CG (0.37) | TGFBR1ACVR1MAPK8CAMKK2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-06-04 | — | — | US | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019142128-A1 | DUAL INHIBITORS OF ALK5 AND P38Α MAP KINASE | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200171030-A1 | DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE | MAP2K2, MAP2K5, MAP2K1 | TGFBR1 27/4885ACVR1B 61/4885ACVRL1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.